Literature DB >> 16967291

Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists.

Gonzalo Romero1, Marta Pujol, Petrus J Pauwels.   

Abstract

The present study reinvestigated a series of 5-HT receptor antagonists at both constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells using the cAMP signalling pathway as a functional read-out. Both rat and human 5-HT7(a) receptors were expressed in similar amounts ([3H]-LSD binding: 1.0 to 1.1 pmol/mg protein). Attenuation of basal cAMP formation by the inverse agonist SB-691673 (1 microM) was slightly larger by the human 5-HT7(a) (-73+/-3 %) than rat 5-HT7(a) receptor (-62+/-3 %). The 5-HT receptor antagonists investigated here displayed systematically inverse agonism. While methiothepin and SB-269970 displayed similar negative intrinsic activity to SB-691673 at the rat 5-HT7(a) receptor, the compounds SB-258719, mesulergine and metergoline displayed some lower negative intrinsic activity (between -38 and -49%). Inverse agonist properties were observed with potencies fitting with their respective binding pIC50 values and pKB values as estimated from antagonist studies with 5-HT. With the exception of SB-258719 and mesulergine, which remained a partial inverse agonist at the human 5-HT7(a) receptor, the other compounds behaved with a similar Emax value to the full inverse agonist SB-691673. In conclusion, none of the 5-HT receptor antagonists investigated displayed silent properties at the rat or human 5-HT7(a) receptor, when these are expressed in a system allowing detection of constitutive activity. They appear to be partial to full inverse agonists, further illustrating that an antagonist is preferentially an inverse agonist when investigated under constitutively active receptor conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16967291     DOI: 10.1007/s00210-006-0093-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).

Authors:  P J Lovell; S M Bromidge; S Dabbs; D M Duckworth; I T Forbes; A J Jennings; F D King; D N Middlemiss; S K Rahman; D V Saunders; L L Collin; J J Hagan; G J Riley; D R Thomas
Journal:  J Med Chem       Date:  2000-02-10       Impact factor: 7.446

2.  The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.

Authors:  Kurt A Krobert; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Differential agonist-mediated internalization of the human 5-hydroxytryptamine 7 receptor isoforms.

Authors:  Chris R Guthrie; Aaron T Murray; Allyn A Franklin; Mark W Hamblin
Journal:  J Pharmacol Exp Ther       Date:  2005-02-16       Impact factor: 4.030

Review 4.  Functional, molecular and pharmacological advances in 5-HT7 receptor research.

Authors:  Peter B Hedlund; J Gregor Sutcliffe
Journal:  Trends Pharmacol Sci       Date:  2004-09       Impact factor: 14.819

5.  Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.

Authors:  Anil Purohit; Carol Smith; Katharine Herrick-Davis; Milt Teitler
Journal:  Psychopharmacology (Berl)       Date:  2004-12-10       Impact factor: 4.530

6.  Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist.

Authors:  J J Hagan; G W Price; P Jeffrey; N J Deeks; T Stean; D Piper; M I Smith; N Upton; A D Medhurst; D N Middlemiss; G J Riley; P J Lovell; S M Bromidge; D R Thomas
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

7.  Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b).

Authors:  J R Jasper; A Kosaka; Z P To; D J Chang; R M Eglen
Journal:  Br J Pharmacol       Date:  1997-09       Impact factor: 8.739

8.  Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.

Authors:  M Ruat; E Traiffort; R Leurs; J Tardivel-Lacombe; J Diaz; J M Arrang; J C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.

Authors:  M Guscott; L J Bristow; K Hadingham; T W Rosahl; M S Beer; J A Stanton; F Bromidge; A P Owens; I Huscroft; J Myers; N M Rupniak; S Patel; P J Whiting; P H Hutson; K C Fone; S M Biello; J J Kulagowski; G McAllister
Journal:  Neuropharmacology       Date:  2005-03       Impact factor: 5.250

10.  High throughput screening technologies for direct cyclic AMP measurement.

Authors:  Daniela Gabriel; Magali Vernier; Martin J Pfeifer; Boris Dasen; Laurent Tenaillon; Rochdi Bouhelal
Journal:  Assay Drug Dev Technol       Date:  2003-04       Impact factor: 1.738

View more
  11 in total

1.  Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.

Authors:  Isabelle Rauly-Lestienne; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-05       Impact factor: 3.000

Review 2.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

3.  Allosteric uncoupling and up-regulation of benzodiazepine and GABA recognition sites following chronic diazepam treatment of HEK 293 cells stably transfected with alpha1beta2gamma2S subunits of GABA (A) receptors.

Authors:  Danka Pericić; Dubravka Svob Strac; Maja Jazvinsćak Jembrek; Josipa Vlainić
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-22       Impact factor: 3.000

4.  Chemosensitivity of Phox2b-expressing retrotrapezoid neurons is mediated in part by input from 5-HT neurons.

Authors:  Yuanming Wu; Katherine L Proch; Frida A Teran; Ryan J Lechtenberg; Harsh Kothari; George B Richerson
Journal:  J Physiol       Date:  2019-03-28       Impact factor: 5.182

5.  Is the 5-hydroxytryptamine 7 Receptor Constitutively Active in the Vasculature? A Study in Veins/Vein.

Authors:  Stephanie W Watts; Emma D Flood; Janice M Thompson
Journal:  J Cardiovasc Pharmacol       Date:  2022-08-01       Impact factor: 3.271

6.  Expression and function of 5-HT7 receptors in smooth muscle preparations from equine duodenum, ileum, and pelvic flexure.

Authors:  Andrea S Prause; Michael H Stoffel; Christopher J Portier; Meike Mevissen
Journal:  Res Vet Sci       Date:  2009-04-11       Impact factor: 2.534

7.  5-HT7 Receptor Restrains 5-HT-induced 5-HT2A Mediated Contraction in the Isolated Abdominal Vena Cava.

Authors:  Romina Gonzalez-Pons; Kiera McRae; Janice M Thompson; Stephanie W Watts
Journal:  J Cardiovasc Pharmacol       Date:  2021-08-01       Impact factor: 3.271

8.  Effect of 5-HT7 receptor blockade on liver regeneration after 60-70% partial hepatectomy.

Authors:  Konstantinos N Tzirogiannis; Kalliopi T Kourentzi; Sofia Zyga; Vassiliki Papalimneou; Maria Tsironi; Agni D Grypioti; Ioannis Protopsaltis; Dimitrios Panidis; Georgios I Panoutsopoulos
Journal:  BMC Gastroenterol       Date:  2014-11-30       Impact factor: 3.067

9.  Allosteric Inhibition of Serotonin 5-HT7 Receptors by Zinc Ions.

Authors:  Grzegorz Satała; Beata Duszyńska; Tomasz Lenda; Gabriel Nowak; Andrzej J Bojarski
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

10.  Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons.

Authors:  Maryam S Vasefi; Kai Yang; Jerry Li; Jeff S Kruk; John J Heikkila; Michael F Jackson; John F MacDonald; Michael A Beazely
Journal:  Mol Brain       Date:  2013-05-14       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.